Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences is a Burlington, Massachusetts drug developer working on roluperidone, a candidate for schizophrenia. It last closed at $2.16 on Nov 17, down 1.82% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From NERV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 14 | Jefferies | Upgrade | Buy | $10 |
| Apr 15 | Citizens | Initiated | Buy | $14 |
Technical Analysis
The stock is 9% below its 20 day and 35% below its 50 day average. It is 122% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $2.04, and the nearest resistance the Pivot R1 at $2.29.
| RSI (14) | 36.83 | Weak, oversold below 30 | Neutral |
| MACD | -0.17 | Above its signal line | Bullish |
| Stochastic | 32.5 | Middle of its range | Neutral |
| ADX (14) | 20.3 | Weak trend | |
| Williams %R | -75.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -131.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −8.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.24 | Typical daily range, 11.1% of price |
| RSI (14) | 28.93 | Oversold below 30 | Oversold |
| MACD | -0.69 | Below its signal line | Bearish |
| Stochastic | 9.1 | Near the bottom of its range | Oversold |
| ADX (14) | 18.3 | No clear trend | |
| Williams %R | -94.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -117.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −48.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.67 | Typical daily range, 31.1% of price |
What happened before
See how NERV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NERV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in NERV in the last 90 days.
NERV Institutional Ownership
Full report →- ▲33 buying vs 11 selling
- ▲Held by funds +1.7 pts
- ▲Funds holding +7
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 65 | 58 | +12.1% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 86.6% | 84.9% | +1.7 pts |
| New / increased | 9 / 24 | 22 / 15 | −10.8% |
| Reduced / sold out | 9 / 2 | 7 / 9 | −31.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NERV is in one of them and how their past NERV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NERV in an article yet. Here's the latest on the wider market.
About Minerva Neurosciences
Minerva Neurosciences is a pharmaceutical company based in Burlington, Massachusetts. Its main focus is roluperidone, a drug candidate being developed to treat negative symptoms of schizophrenia. The candidate is still moving through clinical trials and the U.S. regulatory approval process, so it is not yet approved for sale. The company's intended customers are patients with schizophrenia, along with the doctors and healthcare providers who treat them.
- Headquarters
- Burlington, MA
- Founded
- 2007
- Website
- minervaneurosciences.com ↗


